Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling.

Pastel E, Joshi S, Knight B, Liversedge N, Ward R, Kos K

Nutrition & diabetes12 Dec 2016Cited by 21 (Europe PMC)

PMID27941938PMCIDPMC5223133DOI10.1038/nutd.2016.44PepBankPUB-27941938

Summary

Background/objectivesSubjects with type-2 diabetes are typically obese with dysfunctional adipose tissue (AT). Glucagon-like peptide-1 (GLP-1) analogues are routinely used to improve glycaemia. Although, they also aid weight loss that improves AT function, their direct effect on AT function is unclear. To explore GLP-1 analogues' influence on human AT's cytokine and extracellular matrix (ECM) regulation, we therefore obtained and treated omental (OMAT) and subcutaneous (SCAT) AT samples with Exendin-4, an agonist of the GLP-1 receptor (GLP-1R).Subjects/methodsOMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4. Changes in RNA expression of adipokines, inflammatory cytokines, ECM components and their regulators were assessed and protein secretion analysed by ELISA. GLP-1R protein accumulation was compared in paired AT depot samples.ResultsExendin-4 induced an increase in OMAT adiponectin (P=0.02) and decrease in elastin expression (P=0.03) in parallel with reduced elastin secretion (P=0.04). In contrast to OMAT, we did not observe an effect on SCAT. There was no change in the expression of inflammatory markers (CD14, TNFA, MCP-1), collagens, TGFB1 or CTGF. GLP-1R accumulation was higher in SCAT.ConclusionsIndependently of weight loss, which may bias findings of in vivo studies, GLP-1 analogues modify human OMAT physiology favourably by increasing the insulin-sensitising cytokine adiponectin. However, the reduction of elastin and no apparent effect on AT's inflammatory cytokines suggest that GLP-1 analogues may be less beneficial to AT function, especially if there is no associated weight loss.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In human omental adipose tissue, exendin‑4 increased adiponectin expression.
In plain wordsIn lab tests on human fat tissue, exendin‑4 increased adiponectin expression in omental samples.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOmental adiponectin expression
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Exendin-4 induced an increase in OMAT adiponectin (P=0.02) and decrease in elastin expression (P=0.03) in parallel with reduced elastin secretion (P=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193801
02LabEx vivo tissueMechanism
In human omental adipose tissue, exendin‑4 decreased elastin expression.
In plain wordsIn lab tests on human fat tissue, exendin‑4 reduced elastin expression in omental samples.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOmental elastin expression
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Exendin-4 induced an increase in OMAT adiponectin (P=0.02) and decrease in elastin expression (P=0.03) in parallel with reduced elastin secretion (P=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193802
03LabEx vivo tissueMechanism
In human omental adipose tissue, exendin‑4 reduced elastin secretion.
In plain wordsIn lab tests on human fat tissue, exendin‑4 reduced elastin release in omental samples.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOmental elastin secretion
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Exendin-4 induced an increase in OMAT adiponectin (P=0.02) and decrease in elastin expression (P=0.03) in parallel with reduced elastin secretion (P=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193803
04LabEx vivo tissueMechanism
In human subcutaneous adipose tissue, exendin‑4 showed no effect, unlike the reported omental response.
In plain wordsIn lab tests, exendin‑4 showed no effect on human subcutaneous fat tissue, unlike the reported omental response.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSubcutaneous tissue response
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In contrast to OMAT, we did not observe an effect on SCAT.
2 context sentences(design, population, supporting numbers)
Summary · context
Exendin-4 induced an increase in OMAT adiponectin (P=0.02) and decrease in elastin expression (P=0.03) in parallel with reduced elastin secretion (P=0.04).
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193804
05LabEx vivo tissueMechanism
In human adipose tissue, exendin‑4 did not change expression of the inflammatory marker panel CD14, TNFA and MCP-1.
In plain wordsIn lab tests on human fat tissue, exendin‑4 did not change the reported inflammatory marker panel.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInflammatory marker expression
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
There was no change in the expression of inflammatory markers (CD14, TNFA, MCP-1), collagens, TGFB1 or CTGF.
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193805
06LabEx vivo tissueMechanism
In human adipose tissue, exendin‑4 did not change collagen expression.
In plain wordsIn lab tests on human fat tissue, exendin‑4 did not change collagen expression.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCollagen expression
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
There was no change in the expression of inflammatory markers (CD14, TNFA, MCP-1), collagens, TGFB1 or CTGF.
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193806
07LabEx vivo tissueMechanism
In human adipose tissue, exendin‑4 did not change TGFB1 expression.
In plain wordsIn lab tests on human fat tissue, exendin‑4 did not change TGFB1 expression.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTGFB1 expression
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
There was no change in the expression of inflammatory markers (CD14, TNFA, MCP-1), collagens, TGFB1 or CTGF.
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193807
08LabEx vivo tissueMechanism
In human adipose tissue, exendin‑4 did not change CTGF expression.
In plain wordsIn lab tests on human fat tissue, exendin‑4 did not change CTGF expression.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCTGF expression
Study
humann: not reported in source
Omental and subcutaneous adipose tissue from women undergoing elective surgery
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
There was no change in the expression of inflammatory markers (CD14, TNFA, MCP-1), collagens, TGFB1 or CTGF.
1 context sentence(design, population, supporting numbers)
Summary · context
OMAT and abdominal SCAT samples obtained from women during elective surgery at the Royal Devon & Exeter Hospital (UK) were treated with increasing doses of Exendin-4.
Show in the study text Report a problemFND-2794193808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.